Telix and Eckert & Ziegler Sign US Co-Promotion Agreement for Prostate Cancer Imaging

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 3 June 2021. Telix announces co-promotion agreement with EZAG for Telix’s investigational prostate cancer imaging product Illuccix^® and EZAG’s GalliaPharm^® gallium-68 generator.

Telix is pleased to announce that it has entered into a co-promotion agreement in the United States with Berlin-based Eckert & Ziegler Strahlen und Medizintechnik AG (EZAG) for the combination of EZAG’s GalliaPharm^® (gallium-68 generator) and Telix’s investigational prostate cancer imaging product Illuccix^® (Kit for the preparation of ⁶⁸Ga-PSMA-11 injection).

Under the terms of the agreement, Telix and EZAG will expand their existing collaboration to further develop access to Ga-68 supply in the United States. The parties will co-promote Illuccix^® and GalliaPharm^® to ensure healthcare providers nationwide have secure access to Illuccix^® and Ga-68 generators.

Telix Americas President Dr. Bernard Lambert stated, “This important cooperation between EZAG and Telix sales teams is highly complementary to our efforts in rolling out ⁶⁸Ga-PSMA imaging across the US. Subject to FDA approval, we will together raise awareness of this state-of-the-art imaging modality and facilitate coast-to-coast access for US men living with prostate cancer.”

EZAG Executive Director and responsible for the Medical segment, Dr Harald Hasselmann added, “After previously being granted distribution rights for Germany, our home market, the latest collaboration marks another important milestone for our ⁶⁸Ga generator GalliaPharm^® and our nuclear medicine activities. We are pleased to have Telix as a partner and to be able to jointly deliver leading-edge diagnostic products to prostate cancer patients in the USA.”

To read the full ASX disclosure please click here.

To return to Telix’s homepage please click here.